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Abstract Myeloperoxidase (MPO), an abundant heme enzyme
released by activated phagocytes, catalyzes the formation of a
number of reactive species that can modify low-density
lipoprotein (LDL) to a form that converts macrophages into
lipid-laden or ‘foam’ cells, the hallmark of atherosclerotic
lesions. Since MPO has been shown to bind to a number of
different cell types, we investigated binding of MPO to LDL.
Using the precipitation reagents phosphotungstate or isopropa-
nol, MPO co-precipitated with LDL, retaining its catalytic
activity. The association of MPO with LDL was confirmed using
native gel electrophoresis. MPO was also found to co-precipitate
with apolipoprotein B-100-containing lipoproteins in whole
plasma. No precipitation of MPO was observed in lipoprotein-
deficient plasma, and there was a dose-dependent increase in
precipitation following addition of LDL to lipoprotein-deficient
plasma. Binding of MPO to LDL could potentially enhance site-
directed oxidation of the lipoprotein and limit scavenging of
reactive oxygen species by antioxidants. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Oxidative modi¢cation of low-density lipoprotein (LDL)
trapped within the arterial subendothelial space has been
strongly implicated in the development and progression of
atherosclerosis [1]. Oxidized LDL has a number of potentially
atherogenic e¡ects on vascular cells in culture, including un-
controlled uptake by the scavenger receptors of macrophages,
resulting in the formation of lipid-laden or ‘foam’ cells, the
hallmark of fatty streaks [1]. Although the in vivo mechanisms
of LDL oxidation are not yet fully elucidated, in vitro studies
have shown that various vascular cells, including neutrophils,
monocytes, macrophages, endothelial cells and smooth muscle
cells, can oxidize LDL [1]. These cells contain a number of
enzymes that produce reactive oxygen species [2,3]. The plas-
ma membrane-associated NADPH oxidase reduces extracellu-
lar oxygen to superoxide anion radical [2], which dismutates
to form hydrogen peroxide [2]. Nitric oxide synthase isozymes
generate nitric oxide [3], which reacts rapidly with superoxide
to form peroxynitrite [1]. These reactive oxygen and nitrogen
species, bar nitric oxide [4], have been implicated in cell-medi-
ated LDL oxidation [1,4].
Leukocytes also contain the abundant heme enzyme mye-
loperoxidase (MPO), which is released from storage granules
following activation of the cells by in£ammatory stimuli [2,5].
MPO catalyzes the reaction of hydrogen peroxide with chlo-
ride ions to produce the strong oxidant hypochlorous acid
(HOCl) [5]. Studies have shown that HOCl can modify
LDL to a form that is accumulated by macrophages [6]. Fur-
thermore, HOCl-modi¢ed LDL has a number of other detri-
mental e¡ects on vascular cells, including stimulating in-
creased generation of reactive oxygen species [7^9]. Recent
studies have shown that MPO can also utilize nitrite, the
major aerobic metabolite of nitric oxide, to generate reactive
nitrogen species, most likely nitrogen dioxide radicals [10,11],
and that these reactive nitrogen species can modify LDL to a
form that is recognized by the scavenger receptors of macro-
phages [12].
MPO is a highly cationic protein (pIs 10 [13]) and can
adhere to endothelial cells [13,14], leukocytes [15,16], certain
bacteria [17,18] and yeast [19], with retention of peroxidase
activity. Thus, it is possible that association of MPO with
LDL could potentially enhance site-directed oxidation of the
LDL and limit the scavenging of reactive oxygen and nitrogen
species by antioxidants. Therefore, we have investigated the
binding of MPO to isolated LDL and apolipoprotein B-100
(apoB)-containing lipoproteins in plasma.
2. Materials and methods
2.1. Materials
Human leukocyte MPO was purchased from Calbiochem, La Jolla,
CA, USA. PD-10 gel ¢ltration columns were from Pharmacia Biotech,
Uppsala, Sweden. Native Tris^glycine gels were from Novex, San
Diego, CA, USA. All other reagents were from Sigma Chemical, St.
Louis, MO, USA. Phosphate-bu¡ered saline (PBS) was comprised of
10 mM phosphate bu¡er, 140 mM NaCl, pH 7.4.
2.2. Preparation of plasma, lipoproteins and lipoprotein-de¢cient
plasma
Peripheral blood was drawn from healthy volunteers into vacu-
tainers containing EDTA, heparin, or no addition for serum samples.
To obtain plasma, the blood was centrifuged at 1125Ug for 20 min at
4‡C. LDL and very low-density lipoprotein (VLDL) were isolated
from EDTA-anticoagulated plasma by a sequential centrifugation
method [20], modi¢ed as described previously [21]. The isolated
LDL (1.0196 d6 1.067 g/ml fraction) and VLDL (d6 1.019 g/ml
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fraction) were desalted by two sequential passages through PD-10 gel
¢ltration columns using PBS. The total protein content was deter-
mined using the Lowry Micro Method kit (Sigma P5656). Lipopro-
tein-de¢cient plasma was prepared from the ds 1.21 g/ml fraction of
plasma and was dialyzed at 4‡C against three changes of Chelex-
treated PBS.
2.3. Incubation conditions
MPO, horseradish peroxidase (HRP, type VI-A) and lactoperoxi-
dase (LPO, from bovine milk) were incubated at 50 nM concentra-
tions with LDL (0.5 mg of protein/ml PBS, W1 WM) before addition
of precipitating reagents. Potential inhibitors of complex formation,
such as mannan (from Saccharomyces cerevisiae ; 1 mM) and mixed
alkyltrimethylammonium bromide (Cetrimide; 0.5%), were pre-incu-
bated with both MPO and LDL. MPO was also added to whole
plasma and lipoprotein-de¢cient plasma at ambient temperature.
Known amounts of LDL were added back into the lipoprotein-de¢-
cient plasma using appropriate dilution controls.
2.4. Precipitation techniques
The samples (100 Wl) containing LDL and the peroxidases were
treated with MgCl2 (10 Wl of 0.5 M) and phosphotungstate (10 Wl
of a 4% stock solution in 0.19 M NaOH) to precipitate the LDL
[22]. The samples were centrifuged and peroxidase activity was mea-
sured in the supernatants and the pellets, following resolubilization of
the pellets with 0.1% Tween-20. For the supernatants, numerical val-
ues are presented as a percentage of the control activity in the super-
natant, and for the pellets, values are presented as a percentage of the
activity of control MPO added to resolubilized LDL. Samples were
also treated with an equal volume of isopropanol [23] and peroxidase
activity determined in the supernatants.
2.5. Peroxidase assay
Peroxidase activity was determined using tetramethylbenzidine
(TMB) oxidation [24]. Brie£y, aliquots of the phosphotungstate or
isopropanol supernatants were diluted into 140 Wl of 100 mM acetate
bu¡er, pH 5.4. Samples containing HRP were diluted 100-fold before
addition to the TMB assay. TMB (140 Wl of 2.8 mM, diluted from
5 mg/ml stock in DMSO) and H2O2 (120 Wl of 1 mM) were added and
the samples incubated for 1 min at ambient temperature. Stop bu¡er
(100 Wl of 10 mM azide in 4 N acetic acid) was added and the absor-
bance measured at 655 nm.
2.6. Native gel electrophoresis
Samples were run on Tris^glycine native gels with in-gel protein and
peroxidase staining [25]. Brie£y, 20 Wl samples containing either MPO
(200 nM), LDL (0.2 mg/ml), or both were loaded onto 4^20% Tris^
glycine gels and run for 3 h at 100 V. LDL was detected by protein
staining using Coomassie blue and MPO was detected using in-gel
peroxidase staining. For the latter, the gel was incubated for 10 min
in bu¡er A (comprising 10 mM each of citrate and EDTA, pH 5.0),
15 min in bu¡er B (containing 10% dextran sulfate in bu¡er A), then
washed three times with bu¡er A for 5 min each. The gel was then
incubated in bu¡er C (containing 0.4 ml of 5 mg/ml TMB and 4.7 Wl
of 3% H2O2 per 20 ml of bu¡er A) to detect peroxidase activity.
3. Results
ApoB-containing lipoproteins can be precipitated from
plasma using sulfated polysaccharides such as heparin and
dextran sulfate [26]. However, since both MPO and LDL
bind to sulfated polysaccharides [14,27], precipitation of
LDL with phosphotungstate [22] and isopropanol [23] was
used instead. MPO (50 nM) was incubated at ambient temper-
ature with and without LDL (0.5 mg protein/ml PBS; W1
WM) and enzyme activity was measured in the supernatant
following treatment of the sample with phosphotungstate.
MPO in the absence of LDL was not precipitated by phos-
photungstate, however, following incubation with LDL, only
5% of the added MPO activity remained in the supernatant
(Fig. 1), suggesting that most of the MPO had co-precipitated
with LDL. When the pellet was resuspended in 0.1% Tween-
20, there was almost complete recovery of MPO activity (Fig.
1), indicating that LDL-associated MPO remains catalytically
active. Control experiments showed that 0.1% Tween-20 did
not inhibit or reverse MPO binding to LDL (data not shown).
Time course experiments showed that the binding of MPO to
LDL occurred very rapidly, within the time it took to add the
precipitation reagents (data not shown).
Two other peroxidases, the plant-derived HRP and the
mammalian enzyme LPO, were also incubated at equivalent
concentrations (50 nM) with LDL (Fig. 1). Following precip-
itation of the LDL with phosphotungstate, most of the HRP
activity (85%) remained in the supernatant, whereas very little
of the LPO activity (10%) was detected (Fig. 1). HRP activity
in the pellet was negligible, whereas LPO activity was com-
pletely recovered from the pellet (Fig. 1). Phosphotungstate
did not precipitate HRP or LPO in the absence of LDL (data
not shown).
In agreement with the above ¢ndings, precipitation of LDL
with isopropanol and measurement of peroxidase activity in
the supernatants gave MPO, HRP and LPO activities of 2 þ 1,
Fig. 1. Co-precipitation of MPO with LDL. MPO, HRP and LPO
(50 nM each) were incubated with LDL (0.5 mg protein/ml PBS,
W1 WM) and treated with phosphotungstate to precipitate the
LDL. Peroxidase activity was then measured in the supernatant
(dark bars) and the pellet resuspended in 0.1% Tween-20 (light
bars), using TMB oxidation as described in Section 2. Results are
presented as percent of control MPO activity and are the
mean þ S.D., n = 4.
Fig. 2. Co-migration of MPO with LDL. MPO (200 nM) was incu-
bated with LDL (0.2 mg protein/ml PBS) and run on a 4^20%
Tris^glycine native gel. LDL was detected using Coomassie blue
protein staining, and MPO activity was determined using in-gel per-
oxidase-mediated oxidation of TMB as described in Section 2. Ar-
rows indicate the top of the gel lanes.
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83 þ 21 and 7 þ 10% of controls (mean þ S.D., n = 4), respec-
tively. Comparable results with the three enzymes were ob-
served following phosphotungstate and isopropanol precipita-
tion of the ds 1.019 g/ml fraction of plasma containing
VLDL (data not shown).
To con¢rm that MPO was binding to LDL, the samples
were run on native Tris^glycine gels and peroxidase activity
was measured in the gel using TMB oxidation (Fig. 2). In the
absence of LDL, the MPO did not enter the gel, presumably
due to its charge characteristics (Fig. 2). However, in the
presence of LDL, peroxidase activity was detected in the
gel. There was incomplete co-migration of MPO with LDL
(Fig. 2, TMB oxidation versus apoB staining), likely due to
the opposing electromotive forces of the two proteins.
Since albumin is the major protein in plasma, the e¡ect of
albumin on binding of MPO to LDL was investigated. Addi-
tion of human albumin to MPO and LDL at concentrations
that mimic the situation of human plasma did not inhibit co-
precipitation of MPO with LDL (Fig. 3a), suggesting a spe-
ci¢c or strong interaction between MPO and LDL. Decreas-
ing the concentration of LDL (in the presence of albumin)
resulted in a dose-dependent decrease in the amount of
MPO precipitated (Fig. 3a). Approximately 30% of the
MPO (15 nM) co-precipitated with 10 nM LDL (Fig. 3a,
0.01 LDL), suggesting a ratio of MPO:LDL of about 1.5 in
the presence of physiological concentrations of albumin.
When MPO was added to EDTA-anticoagulated plasma,
approximately 70% of the enzyme activity was precipitated
by phosphotungstate (Fig. 3b); the non-precipitated MPO
(30%) possibly bound to non-apoB proteins in plasma. Com-
parable enzyme activities were observed in precipitates of hep-
arin-plasma and serum (35 þ 1 and 24 þ 10% of control in the
supernatant, and 15 þ 5 and 25 þ 14% in the pellet, respec-
tively, mean þ S.D., n = 3). Interestingly, although about 70%
of the MPO activity in EDTA-plasma was lost, only 30% of
the MPO activity was recovered in the pellet (Fig. 3a), sug-
gesting partial inactivation of the added MPO or interference
by plasma component(s) in the TMB assay. Lipoproteins were
not isolated by ultracentrifugation from plasma to which
MPO had been added because the high salt concentrations
and/or g-forces would have likely disrupted the association
between the lipoproteins and the enzyme.
MPO was next added to lipoprotein-de¢cient plasma. As
shown in Fig. 3b, there was no signi¢cant loss of enzyme
activity following addition of the precipitating reagent.
When LDL was added back to the lipoprotein-de¢cient plas-
ma, there was a concentration-dependent loss of MPO activity
from the supernatant and concomitant recovery of the enzyme
activity in the pellet (Fig. 3b). Similar results were observed
when VLDL was added back into the lipoprotein-de¢cient
plasma (data not shown). When 1.5 mg protein/ml (W3
WM) of apoB-containing lipoprotein was added to lipopro-
tein-de¢cient plasma, a comparable amount of MPO precip-
itation was observed as with whole plasma (Fig. 3b,
LDP+3LDL vs. plasma). Normal human plasma contains ap-
proximately 0.8^1.2 mg/ml (W1.6^2.4 WM) apoB [28].
In order to determine the nature of the MPO/LDL com-
plex, several compounds were pre-incubated with both MPO
and LDL to determine if they could inhibit binding. Mannan
from yeast cell wall has been shown to inhibit the binding of
MPO to both prokaryotic and eukaryotic cells [18,19]. How-
ever, incubation of mannan (1 mM) with MPO and LDL did
not inhibit their subsequent binding (data not shown). Since
MPO is highly cationic (pIs 10), it is possible that the enzyme
is binding to LDL via charge interactions [13,18]. We at-
tempted to examine the e¡ects of high salt concentrations
on the interaction, however, these concentrations of salt in-
terfered with the precipitation techniques used, so the data
were inconclusive. In contrast, pre-incubation with the cation-
ic detergent Cetrimide (0.5%) inhibited co-precipitation of
MPO with LDL and also reversed the binding (75 þ 1% and
81 þ 8% MPO activity in the phosphotungstate supernatant,
respectively, mean þ S.D., n = 4). These data suggest that the
interaction between MPO and LDL is of ionic nature.
4. Discussion
This is the ¢rst study to show that MPO binds to apoB-
containing lipoproteins, including LDL, in isolation and in
human plasma. We found that MPO co-precipitated with
LDL using the precipitating reagents phosphotungstate [22]
and isopropanol [23]. These reagents were used instead of
the sulfated polysaccharides [26] because the latter have
been shown to bind both MPO and LDL [14,27]. Another
Fig. 3. (a) Precipitation of MPO in the presence of albumin. MPO
(50 nM) was incubated in the absence and presence of human se-
rum albumin (HSA, 40 mg/ml) with decreasing amounts of LDL
(0.1^0.001 WM). (b) Precipitation of MPO in whole and lipoprotein-
de¢cient plasma. MPO (50 nM) was incubated with whole plasma
and lipoprotein-de¢cient plasma (LDP); LDL (1.0^3.0 WM) was
added to LPD. For both (a) and (b), the samples were treated with
phosphotungstate to precipitate apoB-containing lipoproteins. MPO
activity was then measured in the supernatant (dark bars) and the
pellet resuspended in 0.1% Tween-20 (light bars), using TMB oxida-
tion as described in Section 2. Results are presented as percent of
control MPO activity and are the mean þ S.D., n = 3.
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mammalian peroxidase, LPO, also co-precipitated with LDL,
in contrast to the plant-derived enzyme, HRP, suggesting spe-
ci¢city of the mammalian peroxidases for LDL. Association
of MPO with LDL was con¢rmed using native gel electropho-
resis. Similar results were observed for the other apoB-con-
taining lipoprotein, VLDL. Physiological concentrations of
albumin, the major plasma protein, did not inhibit co-precip-
itation of MPO with LDL.
Addition of MPO to plasma resulted in precipitation of
approximately 70% of the enzyme activity following addition
of precipitating reagents, whereas no decrease in enzyme ac-
tivity was observed in lipoprotein-de¢cient plasma. That MPO
was binding to apoB-containing lipoproteins was con¢rmed
by adding LDL back into lipoprotein-de¢cient plasma.
When MPO was added to plasma, approximately 30% of
the enzyme was not precipitated, suggesting that some MPO
was binding to plasma proteins other than the apoB-contain-
ing lipoproteins. Several studies have shown that MPO binds
to the plasma metalloenzyme ceruloplasmin [29,30], anti-MPO
immunoglobulins [13,29], and complement fragments [30].
Although not determined, it is possible that MPO is also
able to bind to high-density lipoprotein. Interestingly, binding
to ceruloplasmin inhibits the catalytic activity of MPO [29],
which could account for the less than complete recovery of
MPO activity in the present study [30]. However, interference
by plasma component(s), such as ascorbate, in the TMB assay
cannot be ruled out.
A number of studies have shown that MPO readily adheres
to both prokaryotic and eukaryotic cells in culture [13^19].
Similar binding was observed for the mammalian peroxidases
eosinophil peroxidase (EPO) [31] and LPO [32], but not for
HRP [15], consistent with the ¢ndings of the present study.
LPO shares greater than 50% amino acid homology with the
other cationic peroxidases MPO and EPO [33]. HRP, in con-
trast, exists as a number of isozymes with di¡erent net charges
[34]; the HRP isozyme used in this study, type A, has a pIW4
[34]. Furthermore, all of the above studies [13^19] reported
retention of peroxidase activity upon binding of the MPO to
cells, which we also observed with MPO bound to LDL.
The nature of the interaction between MPO and cells is
most likely of ionic nature [13,18,19]. Studies have shown
that MPO binds to yeast cell wall mannan by interaction
with the phosphate groups of the mannan [35]. Although
mannan was able to inhibit binding of MPO to yeast and
bacteria [18,19], it was unable to inhibit binding of MPO to
leukocytes [15,35] or LDL (this study). Other studies have
shown that cationic compounds can inhibit the binding of
MPO to cells [13,18]. Consistent with this, we found that
the cationic detergent Cetrimide (used in the isolation of
MPO from leukocytes [36]) inhibited the binding of MPO to
LDL. While this suggests that the association is charge-medi-
ated, disruption of the LDL particle by the detergent cannot
be ruled out.
Although LDL is comprised of approximately equivalent
amounts (by weight) of protein and phospholipid [37], it is
not certain whether MPO associates with the protein and/or
lipid component(s) of LDL. ApoB is also a glycoprotein con-
sisting of 8^10% carbohydrate (primarily mannose, galactose,
glucosamine and sialic acid residues) [37], thus it is possible
that MPO is associating with the carbohydrate component of
apoB [38]. Speci¢c interactions between MPO and other gly-
coproteins, such as adhesion molecules, as well as cell surface
receptors, have been reported [15,16]. Binding of MPO to
neutrophils and monocytes was found to occur via the
KML2 integrin [15], and was proposed to mediate leukocyte
adhesion to endothelial cells in culture. MPO was also shown
to be taken up by the mannose receptor of macrophages [16],
suggesting a possible mechanism for clearance of the enzyme.
We attempted to determine the role of the carbohydrate com-
ponent of apoB in binding of MPO using agarose-conjugated
neuraminidase (data not shown), however, since it is di⁄cult
to get consistent and/or complete desialylation using this tech-
nique, the data were inconclusive.
Recent studies have implicated both MPO and MPO-modi-
¢ed LDL in atherosclerosis [39^41]. Immunohistochemical
analysis of human lesions showed the presence of HOCl-
modi¢ed proteins [39], and gas chromatography-mass spec-
trometry (GC-MS) analysis of LDL isolated from human le-
sions showed signi¢cantly increased levels of 3-chlorotyrosine,
a speci¢c marker of HOCl, compared to plasma LDL [40].
Furthermore, 3-nitrotyrosine has been detected in lesions us-
ing immunohistochemistry [42] and GC-MS [43]. While these
results were interpreted initially as evidence for the presence
of peroxynitrite, more recent ¢ndings have shown that MPO
too can generate reactive nitrogen species capable of nitrating
tyrosine residues [44,45]. Catalytically active MPO has been
detected in human atherosclerotic lesions [41] and was found
to be predominantly associated with macrophages in transient
lesions and adjacent to cholesterol clefts in advanced lesions
[41]. Since a majority of the MPO appears to be localized
intracellularly, it is uncertain whether this is due to the en-
zyme not being released, or secreted enzyme being endocy-
tosed. In contrast to MPO, HOCl-modi¢ed proteins have
been reported to be localized extracellularly in human athero-
sclerotic lesions [39]. This has been con¢rmed recently by
Malle et al. [46] who reported co-localization of immunoreac-
tive MPO and HOCl-modi¢ed LDL epitopes in the extracel-
lular matrix and both inside and outside monocyte/macro-
phages and endothelial cells. The possibility of co-uptake of
MPO complexed with LDL has not yet been explored.
A recent study investigating the oxidation of LDL by MPO
versus reagent HOCl found di¡erences in the extent to which
cysteine residues were oxidized [47]. The selective modi¢cation
of apoB by MPO reported in [47] was proposed to be due to
direct interaction of the enzyme with the LDL particle. How-
ever, di¡erences in reactivity due to bolus addition of HOCl
versus continuous production of the oxidant by MPO cannot
be ruled out. Another recent study reported increased oxida-
tion of LDL by MPO in the presence of heparin [48]. These
¢ndings suggest that either interaction of heparin with LDL
modi¢es the lipoprotein structure in a way that increases its
oxidizability, or the negatively charged polysaccharide is en-
hancing association of MPO with the LDL particle. Another
possibility is that heparin-induced alteration in LDL structure
could increase the binding of MPO to LDL. The e¡ects of
other glycosaminoglycans, present in the subendothelial space,
on the association of MPO with LDL are an area for further
investigation.
In this study we have shown that MPO binds to LDL, even
in the absence of sulfated polysaccharides such as heparin.
Binding of MPO to LDL is likely ionic in nature and the
major plasma protein albumin does not inhibit the binding.
The association of MPO with LDL has potentially important
implications with respect to the oxidative modi¢cation of
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LDL, especially in the presence of competing substrates such
as the small molecule antioxidants ascorbate and urate [21,49],
as well as proteins like albumin [50].
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